Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatologic Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynecologic Cancers
Hematology
Hematologic Malignancies
Head and Neck Cancer
Immunotherapy
Leukemia
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Renal Cancer
Endocrine Cancers
Pediatric Oncology
Policy
Sarcoma
Supportive Cancer Care
Soft Tissue Tumors
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 1, 2026

This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging targeted therapies and novel biological insights, the contributions highlight both recent progress and the significant […]

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
touchEXPERT INSIGHTS

Harnessing CAR-T cell therapy to improve outcomes in RRMM

Topics Covered:
Multiple Myeloma
Open Nav

Expert Interviews

The persistent burden and unmet needs in RRMM

Prof. Beatrice Razzo provides an overview of the disease burden of RRMM and existing unmet needs for patients and healthcare systems
Prof. Beatrice Razzo
Duration: 9:34

The evolving RRMM treatment landscape

Prof. Shaji K Kumar discusses the current treatment landscape for RRMM as recommended by global guidelines and outlines current real-world evidence for CAR-T cell therapy in RRMM
Prof. Shaji K Kumar
Duration: 13:06
touchONCOLOGY

Check your Inbox

We've sent your certificate

Back to Activity
Close Popup
touchONCOLOGY

Thank you
for your Feedback!

Back to Activity
Close Popup

Video Navigation

Expert Interviews

The persistent burden and unmet needs in RRMM

Prof. Beatrice Razzo provides an overview of the disease burden of RRMM and existing unmet needs for patients and healthcare systems
Prof. Beatrice Razzo
Duration: 9:34

The evolving RRMM treatment landscape

Prof. Shaji K Kumar discusses the current treatment landscape for RRMM as recommended by global guidelines and outlines current real-world evidence for CAR-T cell therapy in RRMM
Prof. Shaji K Kumar
Duration: 13:06

Activity Overview

Faculty & Disclosures

Activity Overview
Faculty & Disclosures

Overview

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 1–2% of all cancers and remains predominantly incurable despite significant improvements in patient survival over the past 20 years.1,2 Many patients eventually develop relapsed or refractory MM (RRMM), with progression-free survival (PFS) often less than 6 months.1-3 Chimeric Antigen Receptor (CAR) T cell therapy has revolutionised cancer treatment by using the patient’s own genetically modified T cells to specifically recognise and bind to patient-specific tumour antigens.2 Current treatment guidelines recommend prioritising B-cell maturation antigen (BCMA) directed CAR-T cell therapies as first-line immunotherapy for eligible patients with RRMM, while reserving BCMA-targeting bispecific antibodies for subsequent lines or for patients who are not eligible for CAR-T cell therapy, and reserving antibody-drug conjugates for early relapse settings.1, 4-7

There are currently two BCMA-directed CAR-T cell therapies approved for RRMM: ciltacabtagene autoleucel and idecabtagene vicleucel,8,9 both of which have demonstrated high response rates with durable remission, suggesting the potential to achieve long-term disease control in patients with RRMM.7,10,11 Ciltacabtagene autoleucel is the first and only approved second line or later CAR-T cell therapy for adult patients with lenalidomide-refractory MM who have received at ≥1 prior therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, and demonstrated disease progression on prior therapy.8,10 Idecabtagene vicleucel is approved in adult patients with triple-class exposed MM after ≥2 prior treatments including an immunomodulatory agent, a PI, and an anti-CD38 monoclonal antibody.9,11 The mechanism of action of CAR-T cell therapies may help to address unmet medical needs by harnessing the power of the immune system and ciltacabtagene autoleucel may provide physicians with an earlier treatment option at first relapse.2

Learning Objectives

After watching this activity, participants should be better able to:

  • Outline the burden, disease characteristics and remaining unmet medical needs in RRMM, despite significant survival improvements and treatment advances in recent years
  • Understand the current treatment landscape in RRMM and the importance of early diagnosis and treatment initiation
  • Describe how CAR-T cell therapy may help to address the unmet needs for patients with RRMM and provide an alternative option for therapy at first relapse

References11

List View
Grid View
1

Dimopoulos MA, Moreau P, Terposet E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309-322.

2

Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31:667-686.

3

Jagannath S, Martin TG, Lin Y, et al. Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025;43:2766-2771.

4

NCCN Guidelines. Multiple Myeloma, Version 5.2026. Available at: www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (accessed 5 May 2026).

5

Lin Y, Qui L, Usmani S, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25(8)e374-e387.

6

Han L, Wang K, Jiang Z, et al. Recent development in bispecific antibody immunotherapy for hematological malignancies. Crit Rev Oncol Hematol. 2025;212:104752.

7

Puppi M, Sacchetti I, Mancuso K, et al. Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing. Mediterr J Hematol Infect Dis. 2025;17:e2025045.

8

CARVYKTI® (ciltacabtagene autoleucel) Highlights of prescribing information. Available at: www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf (accessed 5 May 2026).

9

Idecabtagene vicleucel. Prescribing information. Celgene Corporation 2021. Available at: www.fda.gov/media/147055/download (accessed 5 May 2026).

10

van de Donk NWCJ, Moreau P, San-Miguel JF, et al. Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network. Hemasphere. 2025;9:e70260.

11

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384:705-716.

Faculty & Disclosures2

Prof. Beatrice Razzo

Thomas Jefferson University, Philadelphia, PA
More Information
Close Popup

Prof. Beatrice Razzo

Thomas Jefferson University, Philadelphia, PA
USA

Biography

Beatrice Razzo, MD, is an Assistant Professor of Medicine at Thomas Jefferson University in Philadelphia, Pennsylvania. Her clinical expertise centres on multiple myeloma and related plasma cell disorders. Her research focuses on clinical and translational strategies to better inform the selection, sequencing and optimal duration of T-cell–redirecting therapies in multiple myeloma. Prof. Razzo has led and contributed to pragmatic clinical trials and real-world studies evaluating teclistamab in relapsed/refractory multiple myeloma, with an emphasis on treatment effectiveness, toxicity and the role of immune fitness.

Disclosures

Advisory board honoraria from Johnson & Johnson. Honoraria from touchMEDICAL.

Prof. Shaji K Kumar

Mayo Clinic Comprehensive Cancer Centre, Rochester, MN

Prof. Shaji K Kumar

Mayo Clinic Comprehensive Cancer Centre, Rochester, MN
More Information
Close Popup

Prof. Shaji K Kumar

Mayo Clinic Comprehensive Cancer Centre, Rochester, MN
USA

Biography

Shaji K. Kumar, MD, is a Consultant in the Division of Hematology and the Mark and Judy Mullins Professor of Hematological Malignancies at the Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Myeloma, Amyloidosis and Dysproteinemia Disease Group at the Mayo Clinic, as well as Research Chair for the Division of Hematology. Prof. Kumar’s research centres on developing new drugs and drug combinations for treating myeloma; he is the Principal Investigator of multiple Phase 1, 2 and 3 clinical trials. Additionally, he studies the mechanisms behind disease progression from precursor conditions and risk stratification of plasma cell disorders. His laboratory aims to understand the role of the bone marrow microenvironment in the development and progression of myeloma. Prof. Kumar serves as Chair of the NCCN Multiple Myeloma Guidelines Panel, and he is the President of the International Society of Amyloidosis and the Vice President of the International Myeloma Society.

Disclosures

Research support for clinical trials from AbbVie, Adaptive, Celgene, Janssen, Kite, MedImmune/AstraZeneca and Takeda. Advisory Board honoraria from AbbVie, Adaptive, Celgene, Janssen, Kite, MedImmune/AstraZeneca, Merck, Novartis, Roche, Sanofi and Takeda. Independent Review Committee participation for Oncopeptides. Honoraria from touchMEDICAL.

Prof. Beatrice Razzo

Thomas Jefferson University, Philadelphia, PA

Video Navigation

Expert Interviews

The persistent burden and unmet needs in RRMM

Prof. Beatrice Razzo provides an overview of the disease burden of RRMM and existing unmet needs for patients and healthcare systems
Prof. Beatrice Razzo
Duration: 9:34

The evolving RRMM treatment landscape

Prof. Shaji K Kumar discusses the current treatment landscape for RRMM as recommended by global guidelines and outlines current real-world evidence for CAR-T cell therapy in RRMM
Prof. Shaji K Kumar
Duration: 13:06

Add a Note

Note Time: 00:00
Save Note
touchONCOLOGY
touchEXPERT INSIGHTS

This content is intended for healthcare professionals only.

Please confirm you are a healthcare professional

Continue
Decline

This activity is supported with funding from Legend Biotech. This activity is provided by touchMEDICAL for touchONCOLOGY.

Close Popup
touchONCOLOGY

Could not verify Country/IP Address.

We were unable to verify your IP address, please try again later. If you are using a method to hide your IP address, such as a VPN or proxy, please disable this and try again.

Return to Homepage

This activity is supported with funding from Legend Biotech.

This activity is supported with funding from Legend Biotech. This activity is provided by touchMEDICAL for touchONCOLOGY.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchMEDICAL to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchMEDICAL of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchMEDICAL activities. touchMEDICAL accepts no responsibility for errors or omissions.

The views and opinions expressed are those of the faculty and do not necessarily reflect those of any sponsor.

Date of preparation: May 2026

Latest articles videos and clinical updates - straight to your inbox

Close Popup